ATYR
Price
$4.32
Change
-$0.11 (-2.48%)
Updated
Feb 21 closing price
Capitalization
362.63M
31 days until earnings call
SLDB
Price
$5.78
Change
-$0.22 (-3.67%)
Updated
Feb 21 closing price
Capitalization
441.12M
Ad is loading...

ATYR vs SLDB

Header iconATYR vs SLDB Comparison
Open Charts ATYR vs SLDBBanner chart's image
aTyr Pharma
Price$4.32
Change-$0.11 (-2.48%)
Volume$1.77M
Capitalization362.63M
Solid Biosciences
Price$5.78
Change-$0.22 (-3.67%)
Volume$2.19M
Capitalization441.12M
ATYR vs SLDB Comparison Chart
Loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATYR vs. SLDB commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Hold and SLDB is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (ATYR: $4.32 vs. SLDB: $5.78)
Brand notoriety: ATYR and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATYR: 180% vs. SLDB: 78%
Market capitalization -- ATYR: $362.63M vs. SLDB: $441.12M
ATYR [@Biotechnology] is valued at $362.63M. SLDB’s [@Biotechnology] market capitalization is $441.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATYR’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 1 green FA rating(s).

  • ATYR’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 1 green, 4 red.
According to our system of comparison, SLDB is a better buy in the long-term than ATYR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATYR’s TA Score shows that 5 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • ATYR’s TA Score: 5 bullish, 4 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ATYR is a better buy in the short-term than SLDB.

Price Growth

ATYR (@Biotechnology) experienced а +26.69% price change this week, while SLDB (@Biotechnology) price change was +43.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

ATYR is expected to report earnings on May 07, 2025.

SLDB is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($441M) has a higher market cap than ATYR($363M). SLDB YTD gains are higher at: 44.500 vs. ATYR (19.337). ATYR has higher annual earnings (EBITDA): -66.11M vs. SLDB (-108.63M). SLDB has more cash in the bank: 171M vs. ATYR (66M). ATYR has less debt than SLDB: ATYR (13.6M) vs SLDB (24.7M). ATYR has higher revenues than SLDB: ATYR (235K) vs SLDB (0).
ATYRSLDBATYR / SLDB
Capitalization363M441M82%
EBITDA-66.11M-108.63M61%
Gain YTD19.33744.50043%
P/E RatioN/AN/A-
Revenue235K0-
Total Cash66M171M39%
Total Debt13.6M24.7M55%
FUNDAMENTALS RATINGS
ATYR vs SLDB: Fundamental Ratings
ATYR
SLDB
OUTLOOK RATING
1..100
9049
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3538
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (41) in the Biotechnology industry is somewhat better than the same rating for ATYR (85) in the null industry. This means that SLDB’s stock grew somewhat faster than ATYR’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATYR (100) in the null industry. This means that SLDB’s stock grew similarly to ATYR’s over the last 12 months.

SLDB's SMR Rating (97) in the Biotechnology industry is in the same range as ATYR (98) in the null industry. This means that SLDB’s stock grew similarly to ATYR’s over the last 12 months.

ATYR's Price Growth Rating (35) in the null industry is in the same range as SLDB (38) in the Biotechnology industry. This means that ATYR’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ATYR (100) in the null industry. This means that SLDB’s stock grew significantly faster than ATYR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATYRSLDB
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
61%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SREAX13.18-0.13
-0.98%
PGIM Select Real Estate A
NQCRX5.11-0.08
-1.54%
Nuveen Large Cap Value Opportunities I
SCCVX13.38-0.34
-2.48%
AB Small Cap Value C
FMDGX33.85-1.19
-3.40%
Fidelity Mid Cap Growth Index
LGLAX47.90-1.78
-3.58%
Lord Abbett Growth Leaders A

ATYR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATYR has been loosely correlated with MGTX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ATYR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATYR
1D Price
Change %
ATYR100%
-2.48%
MGTX - ATYR
37%
Loosely correlated
+6.88%
FBIO - ATYR
34%
Loosely correlated
N/A
SLDB - ATYR
33%
Loosely correlated
-3.67%
SER - ATYR
33%
Loosely correlated
-3.27%
DRUG - ATYR
32%
Poorly correlated
-0.44%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with ALLO. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-3.67%
ALLO - SLDB
41%
Loosely correlated
-3.77%
INZY - SLDB
41%
Loosely correlated
-1.57%
MGTX - SLDB
41%
Loosely correlated
+6.88%
PLRX - SLDB
40%
Loosely correlated
+2.33%
DNTH - SLDB
39%
Loosely correlated
-0.13%
More